Siphoviridae Bacteriophage Bac-FRP-4 for ETBF Infection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Enterotoxigenic Bacteroides fragilis (ETBF) infections are challenging to treat due to increasing antibiotic resistance, and current methods often disrupt normal gut flora, leading to side effects.
Innovation Solution
A composition containing a Siphoviridae bacteriophage, specifically Bac-FRP-4, which is designed to lyse ETBF cells, is used to prevent or treat infections caused by ETBF, minimizing impact on commensal bacteria.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used to treat ETBF infections, then the effectiveness of treatment is reduced due to antibiotic resistance, but using alternative methods like bacteriophages provides high specificity without affecting commensal bacteria
Solution Approach 1:
The patent applies segmentation by using a specific bacteriophage that targets only ETBF bacteria rather than using broad-spectrum antibiotics that affect all bacteria. The bacteriophage is segmented to have high specificity for its target pathogen while leaving commensal bacteria unaffected, thus resolving the contradiction between treatment effectiveness and harm to normal microflora
Solution Approach 2:
The bacteriophage acts as an intermediary agent between the treatment goal and the target bacteria. Instead of直接用 antibiotics that harm both pathogenic and commensal bacteria, the bacteriophage serves as a selective mediator that delivers the therapeutic effect only to ETBF, eliminating side effects on normal microflora
2Productivity
If conventional antibiotics are used, then broad-spectrum antibacterial effects are achieved, but normal microflora is disturbed causing adverse actions
Solution Approach 1:
The patent applies local quality by endowing the bacteriophage with highly specific targeting capability for ETBF bacteria only. The bacteriophage possesses local specificity in its antibacterial action, affecting only the pathogenic bacteria while leaving other bacteria in the microflora completely unaffected, thus achieving broad-spectrum-like productivity without the harmful side effects
3Object-affected harmful factors
If bacteriophages are used to treat ETBF, then high specificity against target bacteria is achieved, but the complexity of selecting appropriate phages increases
Solution Approach 1:
The patent applies self-service by allowing the bacteriophage to naturally recognize and bind to specific surface markers on ETBF bacteria. The bacteriophage possesses inherent self-targeting capability through its structural proteins that automatically identify and attach to complementary receptors on the bacterial surface, eliminating the need for complex external selection processes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Siphoviridae bacteriophage effectively inhibits ETBF proliferation with high specificity, reducing the risk of side effects associated with disrupting normal gut flora, and offering a potentially effective alternative to antibiotics.
Implementation Method 1
Once a bacteriophage infects a bacterial cell, the bacteriophage is proliferated inside the bacterial cell. After proliferation, the progeny of the bacteriophage destroys the bacterial cell wall and escapes from the host bacteria
Data Source
AI summary
A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-4) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.